Ligand acquires milestone and royalty rights to SB206 from Novan

Ligand acquires milestone and royalty rights to SB206 from Novan

Submitted by admin on May 7, 2019 - 10:05am
Source: 
Pharmaceutical Business Review
News Tags: 
Ligand Pharmaceuticals
Novan
SB206
skin infections
Headline: 
Ligand acquires milestone and royalty rights to SB206 from Novan
snippet: 

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum.

Do Not Allow Advertisers to Use My Personal information